Advisors Asset Management Inc. Acquires 342 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Advisors Asset Management Inc. grew its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,669 shares of the company’s stock after buying an additional 342 shares during the quarter. Advisors Asset Management Inc.’s holdings in CRISPR Therapeutics were worth $454,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in CRISPR Therapeutics by 2.9% during the first quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock worth $111,564,000 after buying an additional 46,148 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in CRISPR Therapeutics by 2.1% during the second quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock worth $51,326,000 after buying an additional 19,094 shares during the last quarter. Farallon Capital Management LLC bought a new stake in CRISPR Therapeutics during the second quarter worth about $28,625,000. Baillie Gifford & Co. grew its stake in CRISPR Therapeutics by 2.4% during the second quarter. Baillie Gifford & Co. now owns 405,425 shares of the company’s stock worth $21,897,000 after buying an additional 9,510 shares during the last quarter. Finally, Capital Advisors Inc. OK grew its stake in CRISPR Therapeutics by 8.1% during the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock worth $14,122,000 after buying an additional 22,583 shares during the last quarter. 69.20% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. This trade represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 30,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the sale, the chief executive officer now owns 196,540 shares in the company, valued at approximately $10,931,554.80. The trade was a 13.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,382 shares of company stock worth $1,917,679. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Performance

CRSP opened at $50.84 on Thursday. The firm’s fifty day moving average is $48.02 and its two-hundred day moving average is $51.69. The firm has a market cap of $4.34 billion, a PE ratio of -17.96 and a beta of 1.67. CRISPR Therapeutics AG has a twelve month low of $43.42 and a twelve month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period last year, the business posted ($1.41) earnings per share. Equities analysts forecast that CRISPR Therapeutics AG will post -5.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Thursday, November 7th. Truist Financial decreased their price target on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Royal Bank of Canada reissued a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Finally, Stifel Nicolaus decreased their price target on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $74.94.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.